UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

Annals of oncology, 2014-03, Vol.25 (3), p.592-598

2014

Volltextzugriff (PDF)

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

Annals of oncology, 2019-06, Vol.30 (6), p.1017-1017

2019

Volltextzugriff (PDF)

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

Annals of oncology, 2004-10, Vol.15 (10), p.1527-1534

2004

Volltextzugriff (PDF)

A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)

Leukemia research, 2017-04, Vol.55, p.S147-S148

2017

Volltextzugriff (PDF)

89 A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)

Leukemia research, 2015-04, Vol.39, p.S45-S45

2015

Volltextzugriff (PDF)

111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY

Leukemia research, 2015-04, Vol.39, p.S57-S57

2015

Volltextzugriff (PDF)

88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?

Leukemia research, 2015-04, Vol.39, p.S44-S45

2015

Volltextzugriff (PDF)

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Volltextzugriff (PDF)

112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

Leukemia research, 2015-04, Vol.39, p.S57-S58

2015

Volltextzugriff (PDF)

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5578-5587

2005

Volltextzugriff (PDF)

Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1435-1441

1999

Volltextzugriff (PDF)

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”

Annals of oncology, 2019-06, Vol.30 (6), p.1017-1017

2019

Volltextzugriff (PDF)

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11

Journal of clinical oncology, 1990-09, Vol.8 (9), p.1543-1555

1990

Volltextzugriff (PDF)

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Cancer, 2002-01, Vol.94 (1), p.25-36

2002

Volltextzugriff (PDF)

Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer

International journal of radiation oncology, biology, physics, 2007, Vol.69 (2), p.S137-S137

2007

Volltextzugriff (PDF)

256 - A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)

Leukemia research, 2017-04, Vol.55, p.S147-S148

2017

Volltextzugriff (PDF)

Abstract P6-14-02: A Phase 3 Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel vs. Trastuzumab and Paclitaxel for 1st Line Therapy of HER2+ Metastatic Breast Cancer

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P6-P6-14-02

2010

Volltextzugriff (PDF)

Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia

Journal of clinical oncology, 1987-05, Vol.5 (5), p.722-730

1987

Volltextzugriff (PDF)

Multicenter phase II study of brequinar sodium in patients with advanced breast cancer

American journal of clinical oncology, 1993-12, Vol.16 (6), p.526-528

1993

Volltextzugriff (PDF)

High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study

Journal of clinical oncology, 1987-01, Vol.5 (1), p.75-82

1987

Volltextzugriff (PDF)

Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1425-1434

1999

Volltextzugriff (PDF)

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

Annals of oncology, 2014-03, Vol.25 (3), p.592

2014

Volltextzugriff (PDF)

EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.5510-5510

2006

Volltextzugriff (PDF)

AIDS-related Kaposi’s Sarcoma: A Phase II Study of Liposomal Doxorubicin

Clinical cancer research, 1999-11, Vol.5 (11), p.3432

1999

Volltextzugriff (PDF)

The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab

International journal of radiation oncology, biology, physics, 2005-10, Vol.63, p.S73-S73

2005

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Humans
(31)
Life Sciences & Biomedicine
(31)
Biological And Medical Sciences
(23)
Medical Sciences
(21)
Middle Aged
(20)
Oncology
(20)
Aged
(18)
Adult
(16)
Female
(16)
Antineoplastic Agents
(14)
Pharmacology. Drug Treatments
(14)
Leukemia - Drug Therapy
(12)
Acute Disease
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Male
(11)
Chemotherapy
(10)
Cytarabine - Therapeutic Use
(9)
Cytarabine - Administration & Dosage
(8)
Bone Marrow - Pathology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)

89 A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)

111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY

88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Phase II Trial of High-Dose Liposome-Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”

Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer

256 - A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)

Abstract P6-14-02: A Phase 3 Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel vs. Trastuzumab and Paclitaxel for 1st Line Therapy of HER2+ Metastatic Breast Cancer

Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia

Multicenter phase II study of brequinar sodium in patients with advanced breast cancer

High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study

Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab

AIDS-related Kaposi’s Sarcoma: A Phase II Study of Liposomal Doxorubicin

The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab

Suchergebnisse filtern